ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
0.00%
US Tech 100
19,207.60
1.04%
Dow Jones
40,287.53
0.00%
Brent Oil
81.255
-1.25%
Bitcoin
67,830.86
-0.48%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alkermes PLC (ALKS)

  7. Alkermes PLC (ALKS) News

ALKS

Alkermes (ALKS)

Alkermes PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALKS
DateTimeSourceHeadlineSymbolCompany
07/17/20244:00PMPR Newswire (US)Alkermes to Report Second Quarter Financial Results on July 24, 2024NASDAQ:ALKSAlkermes PLC
07/17/20244:00PMPR Newswire (US)Alkermes to Report Second Quarter Financial Results on July 24, 2024NASDAQ:ALKSAlkermes PLC
06/10/20248:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/10/20248:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/04/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/04/20245:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/04/20244:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/04/20244:51PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/04/20244:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/04/20244:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
06/03/20247:00AMPR Newswire (US)Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
05/31/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
05/29/20244:00PMPR Newswire (US)Alkermes to Participate in Two Upcoming Investor ConferencesNASDAQ:ALKSAlkermes PLC
05/29/20244:00PMPR Newswire (US)Alkermes to Participate in Two Upcoming Investor ConferencesNASDAQ:ALKSAlkermes PLC
05/28/20247:00AMPR Newswire (US)Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
05/28/20247:00AMPR Newswire (US)Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
05/14/20244:30PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALKSAlkermes PLC
05/14/20247:00AMPR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
05/14/20247:00AMPR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
05/02/20247:00AMPR Newswire (US)Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskNASDAQ:ALKSAlkermes PLC
05/01/20247:00AMPR Newswire (US)Alkermes plc Reports First Quarter 2024 Financial ResultsNASDAQ:ALKSAlkermes PLC
04/24/20247:00AMPR Newswire (US)Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1NASDAQ:ALKSAlkermes PLC
04/17/20244:00PMPR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
04/17/20244:00PMPR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
04/09/20247:00AMPR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
04/09/20247:00AMPR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
04/08/20247:00AMPR Newswire (US)Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyNASDAQ:ALKSAlkermes PLC
03/07/20247:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
03/07/20247:00AMPR Newswire (US)Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsNASDAQ:ALKSAlkermes PLC
02/27/20244:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
 Showing the most relevant articles for your search:NASDAQ:ALKS

Your Recent History

USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
BIEL
Bioelectronics (PK)
USOTC
SPZI
Spooz (PK)
USOTC
HIRU
Hiru (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
VPLM
Voip Pal Com (QB)
COIN
BTCUSD
Bitcoin
USOTC
AABB
Asia Broadband (PK)
NASDAQ
LWLG
Lightwave Logic
NASDAQ
COOP
Mr Cooper
USOTC
BLEG
Branded Legacy (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
AMRN
Amarin
NASDAQ
MAXN
Maxeon Solar Technologies
USOTC
DBMM
Digital Brand Media and ... (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved